Literature DB >> 24657939

Nuclear transport of galectin-3 and its therapeutic implications.

Tatsuyoshi Funasaka1, Avraham Raz2, Pratima Nangia-Makker3.   

Abstract

Galectin-3, a member of β-galactoside-binding gene family is a multi-functional protein, which regulates pleiotropic biological functions such as cell growth, cell adhesion, cell-cell interactions, apoptosis, angiogenesis and mRNA processing. Its unique structure enables it to interact with a plethora of ligands in a carbohydrate dependent or independent manner. Galectin-3 is mainly a cytosolic protein, but can easily traverse the intracellular and plasma membranes to translocate into the nucleus, mitochondria or get externalized. Depending on the cell type, specific experimental conditions in vitro, cancer type and stage, galectin-3 has been reported to be exclusively cytoplasmic, predominantly nuclear or distributed between the two compartments. In this review we have summarized the dynamics of galectin-3 shuttling between the nucleus and the cytoplasm, the nuclear transport mechanisms of galectin-3, how its specific interactions with the members of β-catenin signaling pathways affect tumor progression, and its implications as a therapeutic target.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Beta catenin; Galectin-3; Nuclear cytoplasmic transport

Mesh:

Substances:

Year:  2014        PMID: 24657939      PMCID: PMC4108496          DOI: 10.1016/j.semcancer.2014.03.004

Source DB:  PubMed          Journal:  Semin Cancer Biol        ISSN: 1044-579X            Impact factor:   15.707


  158 in total

1.  A novel, nuclear pore-associated, widely distributed molecule overexpressed in oncogenesis and development.

Authors:  V E Gould; N Martinez; A Orucevic; J Schneider; A Alonso
Journal:  Am J Pathol       Date:  2000-11       Impact factor: 4.307

Review 2.  Molecular aspects of cancer cell resistance to chemotherapy.

Authors:  Magali Rebucci; Carine Michiels
Journal:  Biochem Pharmacol       Date:  2013-02-19       Impact factor: 5.858

3.  Cell-surface galectin-3 confers resistance to TRAIL by impeding trafficking of death receptors in metastatic colon adenocarcinoma cells.

Authors:  N Mazurek; J C Byrd; Y Sun; M Hafley; K Ramirez; J Burks; R S Bresalier
Journal:  Cell Death Differ       Date:  2011-09-23       Impact factor: 15.828

4.  Downregulation of beta-catenin by human Axin and its association with the APC tumor suppressor, beta-catenin and GSK3 beta.

Authors:  M J Hart; R de los Santos; I N Albert; B Rubinfeld; P Polakis
Journal:  Curr Biol       Date:  1998-05-07       Impact factor: 10.834

5.  Implication of galectin-3 in Wnt signaling.

Authors:  Tatsuo Shimura; Yukinori Takenaka; Tomoharu Fukumori; Soichi Tsutsumi; Kohji Okada; Victor Hogan; Akira Kikuchi; Hiroyuki Kuwano; Avraham Raz
Journal:  Cancer Res       Date:  2005-05-01       Impact factor: 12.701

6.  The nucleoporin RanBP2 has SUMO1 E3 ligase activity.

Authors:  Andrea Pichler; Andreas Gast; Jacob S Seeler; Anne Dejean; Frauke Melchior
Journal:  Cell       Date:  2002-01-11       Impact factor: 41.582

7.  A novel carbohydrate-based therapeutic GCS-100 overcomes bortezomib resistance and enhances dexamethasone-induced apoptosis in multiple myeloma cells.

Authors:  Dharminder Chauhan; Guilan Li; Klaus Podar; Teru Hideshima; Paola Neri; Deli He; Nicholas Mitsiades; Paul Richardson; Yan Chang; Joanne Schindler; Bradley Carver; Kenneth C Anderson
Journal:  Cancer Res       Date:  2005-09-15       Impact factor: 12.701

Review 8.  The sweet and bitter sides of galectins in melanoma progression.

Authors:  Russell R Braeuer; Einav Shoshan; Takafumi Kamiya; Menashe Bar-Eli
Journal:  Pigment Cell Melanoma Res       Date:  2012-07-12       Impact factor: 4.693

9.  Identification of galectin-3 as a factor in pre-mRNA splicing.

Authors:  S F Dagher; J L Wang; R J Patterson
Journal:  Proc Natl Acad Sci U S A       Date:  1995-02-14       Impact factor: 11.205

10.  Regulation of autophagy by nucleoporin Tpr.

Authors:  Tatsuyoshi Funasaka; Eriko Tsuka; Richard W Wong
Journal:  Sci Rep       Date:  2012-11-20       Impact factor: 4.379

View more
  28 in total

Review 1.  Galectin-3 and cancer stemness.

Authors:  Pratima Nangia-Makker; Victor Hogan; Avraham Raz
Journal:  Glycobiology       Date:  2018-04-01       Impact factor: 4.313

2.  Intra- and intermolecular interactions of human galectin-3: assessment by full-assignment-based NMR.

Authors:  Hans Ippel; Michelle C Miller; Sabine Vértesy; Yi Zheng; F Javier Cañada; Dennis Suylen; Kimiko Umemoto; Cecilia Romanò; Tilman Hackeng; Guihua Tai; Hakon Leffler; Jürgen Kopitz; Sabine André; Dieter Kübler; Jesús Jiménez-Barbero; Stefan Oscarson; Hans-Joachim Gabius; Kevin H Mayo
Journal:  Glycobiology       Date:  2016-02-23       Impact factor: 4.313

Review 3.  How galectins have become multifunctional proteins.

Authors:  Gabriel García Caballero; Herbert Kaltner; Tanja J Kutzner; Anna-Kristin Ludwig; Joachim C Manning; Sebastian Schmidt; Fred Sinowatz; Hans-Joachim Gabius
Journal:  Histol Histopathol       Date:  2020-01-10       Impact factor: 2.303

4.  Tissue and plasma levels of galectins in patients with high grade serous ovarian carcinoma as new predictive biomarkers.

Authors:  Marilyne Labrie; Lorenna Oliveira Fernandes De Araujo; Laudine Communal; Anne-Marie Mes-Masson; Yves St-Pierre
Journal:  Sci Rep       Date:  2017-10-16       Impact factor: 4.379

Review 5.  Galectin-3 in autoimmunity and autoimmune diseases.

Authors:  Felipe L de Oliveira; Mariele Gatto; Nicola Bassi; Roberto Luisetto; Anna Ghirardello; Leonardo Punzi; Andrea Doria
Journal:  Exp Biol Med (Maywood)       Date:  2015-07-03

Review 6.  Galectin-3 in angiogenesis and metastasis.

Authors:  Tatsuyoshi Funasaka; Avraham Raz; Pratima Nangia-Makker
Journal:  Glycobiology       Date:  2014-08-18       Impact factor: 4.313

7.  Galectin-3 is expressed in vascular smooth muscle cells and promotes pulmonary hypertension through changes in proliferation, apoptosis, and fibrosis.

Authors:  Scott A Barman; Xueyi Li; Stephen Haigh; Dmitry Kondrikov; Keyvan Mahboubi; Zsuzsanna Bordan; David W Stepp; Jiliang Zhou; Yusi Wang; Daniel S Weintraub; Peter Traber; William Snider; Danny Jonigk; Jennifer Sullivan; G Ryan Crislip; Joshua T Butcher; Jennifer Thompson; Yunchao Su; Feng Chen; David J R Fulton
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2019-02-06       Impact factor: 5.464

Review 8.  The emerging role of galectins in high-fatality cancers.

Authors:  Cherylane Dubé-Delarosbil; Yves St-Pierre
Journal:  Cell Mol Life Sci       Date:  2017-11-08       Impact factor: 9.261

Review 9.  Galectin-3 regulation of wound healing and fibrotic processes: insights for chronic skin wound therapeutics.

Authors:  Karrington McLeod; John T Walker; Douglas W Hamilton
Journal:  J Cell Commun Signal       Date:  2018-01-25       Impact factor: 5.782

10.  Combination of galectin inhibitor GCS-100 and BH3 mimetics eliminates both p53 wild type and p53 null AML cells.

Authors:  Peter P Ruvolo; Vivian R Ruvolo; Christopher B Benton; Ahmed AlRawi; Jared K Burks; Wendy Schober; James Rolke; George Tidmarsh; Numsen Hail; R Eric Davis; Michael Andreeff
Journal:  Biochim Biophys Acta       Date:  2015-12-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.